Dapadax Vgm 10/100/500mg Tablet

DAPADAX VGM 10/100/500 mg Tablet is a triple fixed-dose combination containing:

• Dapagliflozin (10 mg): An SGLT2 inhibitor that increases urinary glucose excretion

• Metformin (500 mg): A biguanide that reduces hepatic glucose production and improves insulin sensitivity

• Vildagliptin (100 mg): A DPP-4 inhibitor that enhances incretin action, increasing insulin secretion and lowering glucagon

This combination offers a multi-mechanism approach for the effective management of Type 2 Diabetes Mellitus (T2DM).

USES

• For the treatment of Type 2 Diabetes Mellitus in adults

• Indicated when diet, exercise, and dual therapy fail to achieve adequate glycemic control

• Can be used as part of a comprehensive diabetes management plan to improve blood sugar levels

BENEFITS

• Triple mechanism of action targeting different aspects of glucose control:

  • Dapagliflozin: Eliminates excess glucose through urine

  • Metformin: Reduces glucose production by the liver and improves insulin sensitivity

  • Vildagliptin: Enhances insulin secretion in a glucose-dependent manner

• Weight loss or weight neutral effect (especially from dapagliflozin)

• Low risk of hypoglycemia when not combined with insulin or sulfonylureas

• Cardiovascular and renal protective benefits (primarily from dapagliflozin)

• Convenient single-tablet regimen improves patient adherence

SIDE EFFECTS

Common Side Effects:

• Increased urination

• Genital fungal infections

• Urinary tract infections

• Nausea, diarrhea, or abdominal discomfort (mostly due to Metformin)

• Headache

• Upper respiratory tract infections

Less Common / Serious Side Effects:

• Hypoglycemia (especially when used with insulin or sulfonylureas)

• Lactic acidosis (rare but serious, associated with Metformin in renal or liver impairment)

• Diabetic ketoacidosis (rare; linked to SGLT2 inhibitors)

• Pancreatitis (rare; associated with DPP-4 inhibitors)

• Skin rashes or allergic reactions